Shared on27 Aug 25Fair value Increased 14%
Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.
Shared on17 Apr 25Fair value Increased 2.79%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 4.11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Increased 2.74%
AnalystConsensusTarget has decreased revenue growth from 15.7% to 12.0%, decreased profit margin from 28.3% to 23.5% and increased future PE multiple from 30.8x to 47.4x.